Verinurad is under clinical development by AstraZeneca and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Verinurad’s likelihood of approval (LoA) and phase transition for Chronic Kidney Disease (Chronic Renal Failure) took place on 30 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Verinurad Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Verinurad overview

Verinurad (RDEA-3170) is under development for the treatment of chronic kidney disease with preserved ejection fraction and hyperuricemia. It is administered by orally as a capsule. It is a next-generation inhibitor of the URAT1 transporter. It was under development for gout and hyperuricaemia, heart failure. It is a new molecular entity (NME).

AstraZeneca overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

Quick View Verinurad LOA Data

Report Segments
  • Innovator
Drug Name
  • Verinurad
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Genito Urinary System And Sex Hormones
  • Metabolic Disorders
  • Musculoskeletal Disorders
Key Developers
  • Sponsor Company: AstraZeneca
  • Originator: Ardea Biosciences
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.